No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Ipsen S.A. (IPSEY) Q4 2024 Earnings Call Transcript Summary
Ipsen Targets 5%+ Sales Growth and 30%+ Margin for 2025 Amid Strong Pipeline and Launches
Here's the Major Earnings Before the Open Tomorrow
Eton Pharmaceuticals Enters Asset Purchase Agreement To Acquire Increlex (Mecasermin Injection) From Ipsen; No Terms Disclosed
Gilead Wins FDA Nod for Liver Disease Drug
Gilead Exits J&J Royalty Deal for Liver Drug Ahead of Potential FDA Nod